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Toward effective management
Evaluation of both clinical disease severity and health-related 
quality of life (QoL) is paramount to effective management of 
skin diseases such as atopic dermatitis (AD). Clinical disease 
severity is important for assessing treatment response, whereas 
QoL measures are essential for determining the effects of the 
disease and the treatment on a patient’s welfare and daily life. 
Rehal and Armstrong recently conducted a systematic review 
of randomized controlled trials for AD from 1985 to 2010. In 
the 382 studies identified through a search of Medline and 
Scopus databases, 20 disease-severity scales and 14 QoL scales 
were used to monitor the treatment of AD. Use of the four 
most commonly used scales for disease severity (SCORAD, 
EASI, IGA, and SASSAD) increased from 1985 to 2010, and 
this increase coincided with the publication of validation stud-
ies for these scales. Likewise, four QoL instruments (DLQI, 
CDLQI, IDQOL, and DFI) were employed more frequently as 
the years progressed. Overall, this study revealed a promising 
trend of increased usage of validated severity scales and QoL 
instruments over the past decade. (PLoS ONE 6:e17520, 2011) 
Selected by H. Williams
Keep it intact
The use of alternative noninvasive methods of immuno-
therapy for treatment of allergy has received much attention. 
Epicutaneous immunotherapy via a newly described epicu-
taneous delivery system (EDS) has shown promise in children 
allergic to cow’s milk. Dioszeghy and colleagues recently dem-
onstrated that application of ovalbumin to intact skin does not 
lead to passive passage and systemic delivery but does lead 
to capture by skin-resident dendritic cells, migration to lymph 
nodes, activation of immune responses, and production of 
cytokines. Prolonged and repeated applications to sensitized 
animals with the EDS result in downmodulation of the sys-
temic allergen-specific immune response in conjunction with 
an increase in regulatory T cells. These results support the clini-
cal efficacy of this new noninvasive method of immunotherapy 
and suggest that skin may play a tolerogenic role if maintained 
intact. (J Immunol 186:5629–37, 2011) Selected by T. Schwarz
Mast cells get the credit
The sensitizing ability of a compound relies on its capacity 
to provide danger signals and elicit the early innate immune 
response in order to function as an adjuvant and promote the 
induction of the allergen-specific T-cell response. In an effort to 
identify the skin-based cell types that initially sense the haptens 
and mediate these adjuvant effects, Dudeck and colleagues 
developed mice with inducible or constitutive deficiency in 
mast cells (MCs), which are a prime candidate because these 
cells rapidly release proinflammatory mediators. These studies 
revealed that MCs indeed promote contact hypersensitivity. 
In addition, MCs are essential for the adjuvant effects neces-
sary to elicit a T-cell response, and these cells function, at least 
in part, via promotion of induction of the vascular response 
and induction of DC migration during the hypersensitivity 
response. Together, these results indicate that MCs are critical 
for induction of contact allergy. (Immunity 34:973–84, 2011) 
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Cancer stem cell signature
Understanding how mutations of proto-oncogenes or tumor sup-
pressor genes affect cancer stem cells (CSCs) that sustain tumor 
growth via properties of self-renewal and differentiation is key to 
understanding how solid tumors such as cutaneous squamous 
cell carcinoma (SCC) develop. The cell-surface glycoprotein 
CD34, which has been identified on hair follicles and many 
adult stem cells, was used to purify a population of CSC-like 
cells following treatment with the tumor-inducing agents TPA 
and DMBA. Schober and Fuchs found that multiple CSC pools 
with different proliferative potentials exist at the tumor–stromal 
interface in SCCs and that these pools are interconvertible. The 
cycling activities of these CSCs are influenced by their response 
to microenvironmental cues from transforming growth factor-β/
TβRII and integrin/FAK signaling at the interface. Interestingly, as 
integrin expression is attenuated upon departure from the inter-
face, these cells lose their tumor-initiating potential; however, 
transplantation and culture reset the proliferative properties. 
Elucidation of a CSC signature offers not only insights into SCC 
behavior but also a multitude of potential diagnostic and treat-
ment targets. (PNAS 108:10544–9, 2011) Selected by T. Krieg
SIGN of inflammation
Intravenous immunoglobulin (IVIG) functions via binding of IgG 
crystallizable fragments that terminate in sialic acids (sFc) and 
target ICAM-3-grabbing non-integrin-related 1 (SIGN-R1) on 
macrophages to suppress autoantibody-triggered inflammation. 
Anthony and colleagues recently documented the mechanism 
of IVIG suppression of inflammation through a novel T helper 
type 2 cell pathway in a humanized dendritic cell (hDC)-SIGN 
model. The anti-inflammatory activity of IVIG was recapitulated 
by transfer of sFc-pulsed bone marrow–derived macrophages 
or DCs from hDC-SIGN+ mice. These studies supported an 
anti-inflammatory cascade in which DC-SIGN ligation by sFc 
results in IL-33 production, which induces IL-4 expression by 
basophils and results in FcγRIIB upregulation on monocytes 
and macrophages. Accordingly, manipulating the sialylation 
of IgG antibodies to regulate T helper type 2 cytokine produc-
tion by innate myeloid cells in a DC-SIGN-dependent manner 
is an attractive avenue to explore for the development of strate-
gies to suppress inflammation in autoimmune diseases. (Nature 
475:110–3, 2011) Selected by M. Amagai
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